These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. The importance of calcium ions for in vitro malignant hyperthermia testing. Fletcher JE; Huggins FJ; Rosenberg H Can J Anaesth; 1990 Sep; 37(6):695-8. PubMed ID: 2208545 [TBL] [Abstract][Full Text] [Related]
67. Malignant hyperthermia susceptibility in a patient with mitochondrial disorder. Finsterer J; Michalek-Sauberer A; Höftberger R Metab Brain Dis; 2009 Sep; 24(3):501-6. PubMed ID: 19714456 [TBL] [Abstract][Full Text] [Related]
68. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy. Payen JF; Bosson JL; Bourdon L; Jacquot C; Le Bas JF; Stieglitz P; Benabid AL Anesthesiology; 1993 May; 78(5):848-55. PubMed ID: 8489056 [TBL] [Abstract][Full Text] [Related]
69. [A new emphasis on the diagnosis of malignant hyperthermia using the in vitro contracture test?]. Olthoff D; Meinecke CD Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):454-8. PubMed ID: 1786305 [TBL] [Abstract][Full Text] [Related]
70. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland]. Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040 [TBL] [Abstract][Full Text] [Related]
71. Malignant hyperthermia in humans--standardization of contracture testing protocol. Melton AT; Martucci RW; Kien ND; Gronert GA Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643 [TBL] [Abstract][Full Text] [Related]
72. [In vitro diagnosis of malignant hyperpyrexia syndrome]. Eldar I; Goldberg G; Glauber V; Perel A Harefuah; 1991 Dec; 121(12):499-502. PubMed ID: 1794753 [TBL] [Abstract][Full Text] [Related]
73. Xenon does not induce contracture in human malignant hyperthermia muscle. Baur CP; Klingler W; Jurkat-Rott K; Froeba G; Schoch E; Marx T; Georgieff M; Lehmann-Horn F Br J Anaesth; 2000 Nov; 85(5):712-6. PubMed ID: 11094586 [TBL] [Abstract][Full Text] [Related]
74. [Malignant hyperthermia susceptibility in 3 patients with malignant neuroleptic syndrome]. Silva HC; Bahia VS; Oliveira RA; Marchiori PE; Scaff M; Tsanaclis AM Arq Neuropsiquiatr; 2000 Sep; 58(3A):713-9. PubMed ID: 10973114 [TBL] [Abstract][Full Text] [Related]
75. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility. Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578 [TBL] [Abstract][Full Text] [Related]
76. An evaluation of procaine in the treatment of malignant hyperpyrexia. Clarke IM; Ellis FR Br J Anaesth; 1975 Jan; 47(1):17-21. PubMed ID: 1148070 [TBL] [Abstract][Full Text] [Related]
77. [The action of ketamine on muscle contractile behavior. In vitro studies on the musculature of subjects susceptible to malignant hyperthermia]. Hackl W; Winkler M; Mauritz W; Steinbereithner K Anaesthesist; 1989 Dec; 38(12):681-5. PubMed ID: 2619030 [TBL] [Abstract][Full Text] [Related]